NASDAQ Soins de santé Biotechnologie CAI

Caris Life Sciences, Inc.

$ 18.47 3.42 %

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

CEO: David Dean Halbert - https://www.carislifesciences.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$28.6 54.85 %

Recommandation

Buy

DCF

$ -16.56

Loading data...

CAI vs S&P500

Loading data...

No data available.

Quick ratio

7.05

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-6.69

may indicate that the company is undervalued or has poor growth prospects.

EPS

-2.76

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

6.47 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

14.09 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

8.06

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.73

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.44

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
4.35 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
5.71 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.37 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.